Wednesday, March 27, 2013
Gentium SpA, of Villa Guardia, Italy, said a medical team from the National University Corporation Hamamatsu University School of Medicine, Fukushima Medical University, administered defibrotide to the first subject in a Phase I study.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.